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Loss of endothelial adherens junctions is involved in tumor metastasis. Here, we demonstrate that,
in the metastatic Lu1205 melanoma cells, expression of the CD44 variant CD44v8-v10 induced junc-
tion disassembly and vascular endothelial (VE)-cadherin phosphorylation at Y658 and Y731. Short
interfering RNA (siRNA)-mediated CD44 knockdown or sialic acid cleavage reversed these effects.
Moreover, microspheres coated with recombinant CD44v8-v10 promoted endothelial junction dis-
ruption. Overexpression of CD44v8-v10 but not of standard CD44 (CD44s) promoted gap formation
in the non-metastatic WM35 melanoma cells, whereas CD44 knockdown or neuraminidase treat-
ment dramatically diminished melanoma transendothelial migration. Endothelial cells transfected
with the phosphomimetic VE-cadherin mutant Y658E supported transmigration of CD44-silenced
Lu1205 cells. Our ﬁndings imply that CD44 variant isoform (CD44v) but not CD44s regulates endo-
thelial junction loss, promoting melanoma extravasation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor metastasis is a multistep process requiring tumor
detachment from the primary sites, dissemination through the
circulation, lodging onto blood vessel wall and extravasation to
distant organs [1–5]. Within the blood vessel, tumor cell (TC) initi-
ates a complex cascade of adhesive interactions with endothelium.
It requires speciﬁc interactions between endothelial adhesive mol-
ecules and their ligands expressed on TCs [5]. Previous studies
have shown that colon carcinoma cell adhesion to ECs involves
sialylated molecules and integrins [6]. These adhesive interactions
initiate a variety of signal transductions in both cancer and
endothelial cells (ECs) [6–8].CD44 is an N- and O-glycosylated cell surface protein [9,10].
CD44s is composed of 341 amino acids with a molecular mass of
85–90 kD [11]. At least ten exons (v1–v10) can be alternatively
spliced to give rise to multiple CD44 variant isoform (CD44v) with
a variety of molecular weights [12,13]. The expression of CD44 has
been found to be associated with tumor progression, tumor
immune evasion, receptor tyrosine kinase (RTK)-induced activa-
tion of anti-apoptotic pathways, and cancer-initiating cell survival
[10,14]. The expression of CD44v confers breast cancer and colon
carcinoma metastatic potentials [4]. CD44 was originally identiﬁed
as a leukocyte homing receptor, and its extracellular amino-
terminal domain contains hyaluronic acid (HA)-binding motifs
and several N-glycosylation sites which may mediate CD44-HA
binding [15–18]. CD44 possesses distinct sialofucosylated modiﬁ-
cations with different binding afﬁnities for selectins under static
and hydrodynamic conditions [3,5]. CD44s can bind to E-selectin
but not L- or P-selectin, whereas CD44v is a ligand for all three,
mediating initial tethering of carcinoma cells to platelets and ECs
[12,13]. CD44-ﬁbrin interactions are required for sustained TC
adhesion, ultimately leading to tumor extravasation and establish-
ment of secondary tumor loci [19].
Intact endothelial monolayer is maintained by vascular endo-
thelial-cadherin (VE-cadherin) homophilic interactions in adher-
ens junctions [20]. Endothelial junction integrity is disrupted by
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dissociation of the p120 and b-catenin complex from the cytoplas-
mic tails of VE-cadherin [21,22]. VE-cadherin dimer disassembly
plays an essential role in angiogenesis, tumor metastasis, cellular
mesenchymal state maintenance, and endothelial viability
[9,10,23–25]. Previous studies indicated that disassembly of VE-
cadherin homodimers is mediated by adhesion events [26,27].
Tumor cell adhesion initiates a series of signaling cascades leading
to loss of endothelial junction integrity [28–30]. Studies also sug-
gested that VE-cadherin phosphorylation was coupled with junc-
tion breakdown in response to external stimuli [31,32]. Upon
phosphorylation of VE-cadherin at tyrosine residues, Y658 and
Y731, p120 and b-catenin were dissociated from VE-cadherin
cytoplasmic domains [21,23,32–34]. Although the loss of adherens
junction integrity has been shown to promote melanoma-lung
metastasis in mouse model, the molecular basis of the underlying
mechanism remains elusive.
In the current study, we demonstrated that highly metastatic
melanoma cell line Lu1205 but not non-metastatic cell line
WM35 facilitated endothelial junction breakdown and
VE-cadherin phosphorylation at tyrosine resides, Y658 and Y731.
The differences in the capacities of these cells to regulate junction
integrity were attributed to the presence of spliced variant
CD44v8-v10 on Lu1205. Short interfering RNA (siRNA) silencing
and enzymatic digestion assays suggested that CD44 plays a major
role in VE-cadherin junction disassembly. Overexpressing CD44v8-
v10 but not CD44s in WM35 elevated the ability of WM35 to
induce EC junction breakdown. Our results further revealed that
by initiating VE-cadherin phosphorylation and junction break-
down, CD44v8-v10 on Lu1205 mediates melanoma transendothe-
lial migration.
2. Materials and methods
2.1. Cell culture
Human umbilical vein endothelial cells (HUVECs) were
obtained from American Type Culture Collection (ATCC) (Manas-
sas, VA) and maintained in F12-K medium with 10% FBS, 30 lg/
ml of endothelial cell growth supplement, 50 lg/ml heparin (Mal-
linckrodt Baker), and 100 U/ml of penicillin–streptomycin (Bioﬂ-
uids). The Lu1205 melanoma cell line and HL-60 human myeloid
cells (obtained from ATCC) were maintained in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM; GIBCO) and Iscove’s Modiﬁed
Dulbecco’s Medium (IMEM) supplemented with 10% FBS and
100 U/ml of penicillin–streptomycin. SK-Mel-25 (ATCC) and
WM35 melanoma cells (provided by Dr. Meenhard Herlyn, Wistar
Institute, Philadelphia, PA) were maintained in Roswell Memorial
Park Institute (RPMI) supplemented with 10% FBS and 100 U/ml
of penicillin–streptomycin. All cells were maintained in a humidi-
ﬁed incubator at 37 C and 5% CO2.
2.2. Extraction of CD44 and preparation of CD44-coated polystyrene
beads
Cell membrane proteins were isolated by using a MEM-PER
Membrane Protein Extraction Kit (Pierce, Rockford, IL) following
the manufacturer’s instructions. Brieﬂy, cells were lysed with
detergent in the presence of protease inhibitors and EDTA. Then,
a second detergent was added to solubilize the membrane pro-
teins. Following differential centrifugation and incubation at
37 C, hydrophobic proteins were separated from the hydrophilic
proteins through phase partition. Western blotting was used to
determine the extraction efﬁciency. To immunoprecipitate CD44
isoforms, anti-human CD44H (clone 2C5, R&D, Minneapolis, MN)antibody was crosslinked to protein G coupled Dynabeads (Invitro-
gen) with Bis(sulfosuccinimidyl) substrate (BS3) (Thermo Scien-
tiﬁc). Then, the hydrophobic phase was incubated with anti-
CD44-Dynabeads overnight at 4 C. To elute CD44 from the beads,
Ab-Ag-beads were washed 6 times with 2% NP-40/1% bovine
serum albumin (BSA), followed by 3 times with lysis buffer con-
taining 2% NP-40. Immunoprecipitates were diluted with phos-
phate buffered saline (PBS)/0.02% sodium azide and heated to
95 C to elute CD44. Immunoprecipitated CD44 was then coated
onto 15 lm polystyrene beads (Polysciences Inc., Warrington, PA)
with carbonate/bicarbonate buffer. After washing with PBS/BSA,
the coating efﬁciency on the microspheres was determined by ﬂow
cytometry. A calibration curve was established with QuantiBRITE
Quantitation Kit (BDBiosciences) to relate the mean ﬂuorescence
intensity to the number of molecules bound per particle. The
CD44 isoform site densities on beads were comparable to those
of Lu1205. Beads were resuspended (1  106 microspheres/ml) in
PBS/0.1% BSA for use in co-culture assays.
2.3. Flow cytometry
Cells were detached with trypsin carefully and incubated with
BSA to block non-speciﬁc binding sites. Cells were then incubated
with saturating concentrations of primary mAbs directed against
speciﬁc molecules in PBS containing 1% BSA for 20 min at 4 C.
Cells were then washed twice to remove unbound primary anti-
bodies. After an additional 20 min incubation with Alexa-546 con-
jugated goat anti-mouse Fab2 fragment (1 lg/106 cells; Invitrogen)
at 37 C, the cells were washed twice and ﬁxed with 2% formalde-
hyde and analyzed using a GUAVA personal ﬂow cytometry
(GUAVA Technologies, Burlingame, CA).
2.4. Western blotting
Melanoma and HUVECs were collected and rinsed with PBS, and
lysed with RIPA lysis buffer (20 mM Tris, 5 mMMgCl2, 1 mM PMSF,
20 mg/ml aproptonin, 10 mg/ml leupeptin, 1 mM Na3VO3, and
20 mM b-glycerophosphate). The lysates were centrifuged at
14000 rpm for 15 min. The protein concentrations across samples
were checked by Bradford method. The samples were denatured by
adding SDS running buffer (0.2% bromophenol blue, 4% SDS,
100 mM Tris[pH 6.8], and 20% glycerol) and b-mercaptoethanol.
The samples were analyzed by SDS–PAGE on 12% gels. After the
proteins were transferred to nitrocellulose membrane, green ﬂuo-
rescence protein (GFP) (Abcam, Eugene, OR), CD44 (clone 2C5),
CD44v7/8 (VFF-17, Serotec, Inc., Raleigh, NC), CD44v10 (Millipore,
Billerica, MA), or CD44s (156-3C11, Serotec, Inc., Raleigh, NC),
phosphorylated VE-cadherin (Y658) (Chemicon, Temecula, CA),
phosphorylated VE-cadherin (Y685) (ECM Biosciences, Versailles,
KY), and phosphorylated VE-cadherin (Y731) (Chemicon, Temecu-
la, CA) were detected with corresponding primary monoclonal
antibodies (1:1000 diluted in blocking buffer) followed by HRP
conjugated secondary antibodies. The labeled proteins were visual-
ized using a chemiluminescence kit. Thereafter, membranes were
stripped with stripping buffer before being reprobed with anti-b-
tubulin (Cell Signaling Technology, Massachusetts, MA) to ensure
equal loadings.
2.5. Immunoﬂuorescence staining
Before experiments, 25-mm cover slips were coated with ﬁbro-
nectin (1 lg/ml). Equal amounts of HUVECs were then grown to
95–99% conﬂuency. After co-culture experiments, HUVECs were
then washed two times with PBS and ﬁxed with 5% formaldehyde
in PBS for 10 min. Following ﬁxation, cells were permeabilized
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anti-VE-cadherin (Cell Signaling Technology, Massachusetts, MA)
in 0.3% Triton X-100/PBS (dilution of 1:100) overnight at 4 C.
Cover slips were then washed with PBS and treated with Alexa
Fluor 488 goat anti-mouse IgG antibody (dilution of 1:1000). The
cells were counter-stained with 40,6-diamidino-2-phenylindole
(DAPI). The cells were imaged under a Nikon TE2000-U inverted
microscopy (Nikon Instruments, Inc.). For each experimental con-
dition, one cover slip was viewed under a 100 objective, and a
series of six images were taken of randomized ﬁelds of view. Each
image was then analyzed using Image J software.
Disruption of VE-cadherin was identiﬁed from analysis of dis-
continuity of green ﬂuorescence at VE-cadherin junctions between
HUVECs. Gap area within disrupted VE-cadherin junctions was
determined from six images. Gap area was quantiﬁed as the ratio
of pixels within all the gaps to the total number of pixels of an
image.
2.6. siRNA targeting CD44
siRNA (100 pmol) was introduced into 1  106 Lu1205 via
nucleofection with an AmaxaNucleofector (Koeln, Germany). Solu-
tion R/program K-17 was used for Lu1205. The resultant transfec-
tion efﬁciency following nucleofection was >90%. Duplexed Stealth
siRNA (Invitrogen) was used for these studies. The sequence for
each respective siRNA is as follows: scrambled, 50-
AAUUCUCCGAACGUGUCACGUGAGA-30; CD44, 50-AUG-
CAAUGUGCUACUGAUUGU-30. Following nucleofection, cells were
replated and, 72 h later, protein lysates were harvested for Wes-
tern blot analysis.
2.7. Soluble CD44 cDNA construction and CD44 transfection
cDNA clones of human CD44 isoforms containing standard
exons only (CD44s) and exons v8–v10 (CD44v8-v10) were
obtained from Origene (Rockville, MD). The cDNA constructs were
inserted into the expression vector pCDNA3.1(Invitrogen). The
constructs were transfected into COS-7 or WM35 cells with Miru-
sTransIT (Mirus Bio LLC.) and then subjected to G418 selection for
2–3 weeks. Expression of the transfected constructs was assessed
by Western blot analysis.
Soluble CD44s and CD44v8-v10 were generated by introducing
TGA stop condon to 30 end of 16 exon to obtain a secreted CD44
molecule which is devoid of the transmembrane and cytoplasmic
domain [15,35]. The truncated cDNA was cloned into pcDNA3.1.
The plasmid DNA was analyzed by sequencing. COS-7 cells were
transfected with 20 lg plasmid DNA. The expressions of constructs
were assessed by Western blotting and ELISA of cell supernatant.
Soluble CD44 in the cell culture supernatant for 48 h growth were
collected and concentrated with Centricon 100 columns with a
molecular weight cutoff of 30 kD. After dialysis with Slide-A-dialy-
sis cassette (Thermo Scientiﬁc) against PBS, the soluble CD44 was
coated to microspheres for co-culturing study.
2.8. Construction of phosphomimetic VE-cadherin mutants and
transfection of cell lines
Human VE-cadherin cDNA was obtained from Sino Biological
Inc. (Beijing, China). The terminal stop codon with a single base
deletion was generated with Quickchange site-directed mutagene-
sis kit (Stratagene). This construct was fused with enhanced green
ﬂuorescence protein (EGFP) (pEGFP-N2 plasmid; Clontech) with an
EagI site. VE-cadherin-EGFP was subcloned into pcDNA3.1. Y-E
mutation of VE-cadherin was created by site-directed mutagenesis.
Constructs were conﬁrmed by DNA sequencing. Native
VE-cadherin migrates at 140kDa in SDS–PAGE. The fusion proteinwas anticipated to migrate at 170kDa with the added mass of
the EGFP tag. Plasmids were transfected into HUVEC with
MirusTransIT. Transfection efﬁciency was assessed with Western
blotting. Stable cell lines were selected with 800 lg/ml G418.
2.9. Enzyme cleavage
To remove terminal sialic acid residues, melanoma cells were
incubated with 0.1 U/ml Vibrio cholera neuraminidase (Sigma–
aldrich, St. Louis, MO) for 90 min at 37 C. To cleave chondroitin
sulfate from CD44 isoforms, cells were incubated for 2 h at 37 C
with 1 U/ml Proteus vulgaris chondroitinase ABC. Site densities of
relevant sugar groups on tumor cell CD44 molecules following
enzymatic treatments were determined by ﬂow cytometry to
conﬁrm enzyme cleavage efﬁciency.
2.10. Metabolic inhibition
Cells were pretreated with 0.1 U/ml V. cholerae neuraminidase
for 60 min at 37 C to remove terminal sialic acid residues [12].
Then, cells were cultured for 48 h at 37 C in medium containing
either 2 mM benzyl-2-acetamido-2-deoxy-a-D-galactopyranoside
(benzyl-GalNAc) (Sigma) to inhibit O-linked glycosylation or
1 mM deoxymannojirimycin (DMJ) (Sigma) to disrupt N-linked
posttranslational modiﬁcations. PBS was used for control
untreated cells.
2.11. Micropipette binding assay
A micropipette frequency assay was used to measure the bind-
ing of E-selectin and CD44 [36]. Human red blood cells (RBCs) were
isolated from whole blood using EDTA-containing vacutainer fol-
lowing the Pennsylvania State University Institutional Review
Board (IRB)-approved protocols (No. 31120). E-selectin-Fc chimera
(R&D) was coupled onto the RBC membrane by a modiﬁed chro-
mium chloride (CrCl3) coupling protocol. Then an E-selectin coated
RBC was gently aspirated by a micropipette and a CD44-coupled
bead was held by another micropipette. The micropipette holding
the RBC was driven by a computer-programmed piezoelectric actu-
ator to make repeated contacts with the bead with a contact dura-
tion of 5 s. The presence of adhesion between the RBC and bead
was detected by the membrane deﬂection when the RBC was
retracted from the bead. The adhesion frequency was counted by
repeating the contact for 100 times of each pair of RBC-bead.
2.12. Transmigration assay
Tumor transmigration was assessed in a Boyden chamber.
HUVECs were grown to conﬂuency on ﬁbronectin-coated polyvi-
nylpyrrolidone-free polycarbonate ﬁlters (8 lm pore size; Neurop-
robe). The wells on the bottom plate of the chamber were ﬁlled
with HUVEC media with 2% FBS, and the middle 12 wells were
ﬁlled with collagen type IV (100 lg/ml in RPMI with 1% BSA) to
act as a chemoattractant to melanoma cells [37,38]. Melanoma
cells were then loaded in wells on the top plate of the migration
chamber in the middle 12 wells. After incubation at 37 C for 4 h,
the number of melanoma cells migrating through the endothelial
layer on the bottom of the ﬁlter was counted by staining the cells
with Protocol Brand Hema 3 solution (Fisher Scientiﬁc) and count-
ing stained cells using an inverted microscope (Diaphot 330;
Nikon) with Image J software.
2.13. Statistical analysis
Data were obtained from at least three independent experi-
ments and are expressed as means ± S.E.M. Statistical signiﬁcance
Fig. 1. CD44v8-v10 is highly expressed on Lu1205 cells. (A) Western blotting analysis of the presence of CD44 isoforms on WM35, HL-60, SK-Mel-25 and Lu1205 cells with
2C5 antibody. CD44v: 150 kD; CD44s: 100 kD. (B) Western blotting analysis of the expression of CD44v on Lu1205 cells with antibodies speciﬁc to different CD44 variant
isoforms. (C) Percentage of endothelial gap formation induced by co-culturing HUVEC with Lu1205 or SK-Mel-25 for 90 min. ⁄⁄P<0.01 compared with SK-Mel-25. All results
are expressed as mean ± S.E.M. and representative of at least three independent experiments.
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t-test or analysis of variance (ANOVA). Turkey’s test was used for
post hoc analysis for ANOVA. Probability values of P < 0.05 and
P < 0.01 were chosen as statistical signiﬁcant.
3. Results
3.1. The adhesion of metastatic melanoma cells mediates VE-cadherin
junction disassembly
Endothelial junction breakdown is an important step controlling
tumor metastasis. To assess the ability of melanoma cells with dif-
ferentialmetastatic potentials to induce the loss of endothelial junc-
tion integrity, metastatic melanoma Lu1205 and non-metastatic
melanomaWM35 were co-cultured with HUVECs in direct contact.
The immunoﬂuorescence staining of VE-cadherin showed that VE-
cadherin junction remained intact when HUVECs were co-cultured
with WM35 (Supplementary Fig. 1A). In contrast, endothelial VE-
cadherin junctionwas disrupted upon Lu1205 contact. VE-cadherin
staining was dim along the periphery of HUVECs, suggesting that
VE-cadherin might be internalized. 1X106 Lu1205 but not WM35
in direct contact with HUVEC monolayer induced endothelial gap
formation in a time-dependent manner (Supplementary Fig. 1B).
HUVEC gap size was increased by 15 folds upon co-culturing
HUVECs and Lu1205 for 90 min. Concomitantly, Lu1205 contact
triggered a dramatic increase in VE-cadherin phosphorylation at
tyrosine residues, Y658 and Y731, but not Y685 (SupplementaryFig. 1C). Therefore, melanomametastatic potentials were correlated
with their abilities to regulate VE-cadherin phosphorylation and
junction breakdown. VE-cadherin disassembly was not primarily
mediated by soluble factors, as junction integrity was insensitive
to 24-h tumor conditioned medium (TCM) treatment (Supplemen-
tary Fig. 1D).
Since tumor-derived soluble factors did not play a role in medi-
ating gap formation, we postulated that melanoma cells might
express certain receptors to initiate signal transduction in EC.
Recently, studies have demonstrated that CD44 in LS174T colon
carcinoma cells possesses selectin binding activity, suggesting a
role for CD44 in mediating tumor metastasis, particularly in the
process of extravasation [12,13]. Lu1205, promyelocytic leukemia
cell HL-60 and a third melanoma cell SK-Mel-25 expressed appre-
ciable amounts of CD44 on their surface, while the presence of
CD44 was not detectable on WM35 cells (Supplementary
Fig. 2A). Western blotting analysis revealed that 2C5 antibody rec-
ognized both CD44v and CD44s on Lu1205 which appeared as
intense bands at 150 kD and 100 kD on immunoblots
(Fig. 1A). Only the standard isoform of CD44 is expressed on SK-
Mel-25 and HL-60 cells. To identify the status of the particular
CD44 splice variants on tumor cells, we blotted Lu1205 membrane
receptors with a panel of antibodies that speciﬁcally recognize
different spliced isoforms of CD44 (i.e. CD44H, CD44v7/8 and
CD44v10). Anti-CD44v7/8 and anti-CD44v10 simultaneously
reacted with a 150 kD protein, but not other proteins (Fig. 1B).
This implies that CD44v is spliced as a single 150 kD molecule
Fig. 2. CD44 and sialic acid motifs on Lu1205 melanoma cells promote EC gap formation and trigger VE-cadherin phosphorylation. (A) Western blotting analysis of CD44
knockdown efﬁciency mediated by siCD44 with 2C5 antibody. (B) Percentage of endothelial gap formation induced by co-culturing HUVECs with buffer, scrambled siRNA or
CD44-siRNA-transfected Lu1205 for 90 min. ⁄⁄P < 0.01 compared with control cases. siCD44: CD44 siRNA. (C) Western blotting analysis of VE-cadherin phosphorylation at
Y658, Y685 and Y731 on HUVECs being co-cultured with buffer, scrambled siRNA or CD44-siRNA-transfected Lu1205 for 90 min. b-tubulin served as a loading control. The
values of relative VE-cadherin phosphorylation levels for densitometric analysis are shown under each band. (D) Percentage of endothelial gap formation induced by co-
culturing HUVECs with Lu1205 which were pre-treated with PBS, 0.1 U/ml neuraminidase or 1 U/ml chondroitinase AC for 90 min. ⁄P < 0.05 compared with PBS. (E) Western
blotting analysis of VE-cadherin phosphorylation at Y658, Y685 and Y731 on HUVECs being co-cultured with Lu1205 which were pre-treated with PBS, 0.1 U/ml
neuraminidase or 1 U/ml chondroitinase AC for 90 min. b-tubulin served as a loading control. The values of relative VE-cadherin phosphorylation levels for densitometric
analysis are shown under each band. Chon: chondroitinase AC; Neu: neuraminidase. All results are representative of at least three independent experiments.
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conﬁrmed by exon-exon spanning real-time PCR which shows that
CD44v8-v10 but not CD44v2-v10 and CD44v3-v10 isoforms were
highly expressed in Lu1205 (Supplementary Fig. 2B). CD44s +
CD44v8-v10+ cell line, Lu1205, induced signiﬁcantly larger gap for-
mation than CD44s + CD44v8-v10-cell line, SK-Mel-25, suggesting
that CD44v8-v10 but not CD44s is required for melanoma-medi-
ated endothelial junction breakdown (Fig. 1C).
3.2. Targeting CD44 with siRNA or digesting sialic acid on Lu1205
reduced endothelial gap formation and VE-cadherin phosphorylation
Since CD44 isoforms can bind to E-, P- and L-selectins which are
expressed on endothelium [12,13,39], we hypothesized that CD44was involved in Lu1205-mediated endothelial junction breakdown.
To determine the function of CD44, we silenced CD44 in Lu1205
priori to co-culture experiments. Transfecting Lu1205 cells with
CD44 siRNA led to a signiﬁcant reduction (>90% decrease) in sur-
face expression of CD44 relative to scrambled siRNA-transfected
cells (Fig. 2A). After transfection, the cell morphology was not
changed. Cells maintained their typical spindle shapes. Annexin
v/7-ADD staining revealed that the cell viability in siRNA-transfec-
ted group was 98%.
Targeting CD44 by siRNA in Lu1205 cells signiﬁcantly reduced
melanoma-induced endothelial gap formation (P < 0.01) (Fig. 2B).
In addition, CD44 silencing attenuated melanoma-mediated VE-
cadherin phosphorylation at Y658 and Y731 (Fig. 2C). Since CD44
is posttranslationally modiﬁed by polysaccharides [12,19],
Fig. 3. CD44v8-v10-coated microspheres mediate EC gap formation. (A) Site densities and expression levels of CD44 on CD44-coated microspheres and Lu1205 cells as
determined by ﬂow cytometry with 2C5 antibody. (B) Percentage of endothelial gap formation induced by co-culturing HUVECs with microspheres coated with BSA, HL-60-
CD44s or Lu1205-CD44. ⁄⁄P < 0.01 compared with BSA-coated microspheres. All results are expressed as mean ± S.E.M. from three independent experiments. (C) Schematic
drawing of the different CD44 cDNAs being transfected into COS-7 cells. The standard exons 1–5 and 16–19 are depicted as orange and cyan boxes, while alternatively spliced
exons v8-v10 are marked as white boxes. For the soluble CD44s and CD44v8-v10 cDNA, a TGA stop condon was inserted 30 to exon 16. (D) Site densities and expression levels
of CD44 isoforms on soluble CD44-coated microspheres, membrane-bound CD44 microspheres and Lu1205 cells determined by ﬂow cytometry with anti-CD44v7/8, anti-
CD44v10 and anti-CD44s antibodies. Soluble CD44s and CD44v8-v10 secreted from transfected COS-7 cells were concentrated and coated onto microspheres. Membrane-
bound CD44s and CD44v8-v10 were immunoprecipitated with 2C5 antibody from transfected-COS-7 cells and coated onto microspheres. (E) Percentage of endothelial gap
formation induced by co-culturing HUVECs with microspheres coated with soluble or membrane-bound CD44 isoforms. ⁄P < 0.05 compared with CD44s-coated microspheres.
All results are expressed as mean ± S.E.M. from three independent experiments. (F) Percentage of endothelial gap formation induced by CD44-coated microspheres generated
by using CD44 immunopuriﬁed from soluble or membrane-bound CD44-transfected COS-7 cells treated with metabolic inhibitors. CD44-transfected cells were pretreated
with 0.1 U/ml neuraminidase to cleave sialic acid. Then, cells were subsequently cultured for 48 h in medium containing PBS (control), 1 mM DMJ, or 2 mM benzyl-GalNAc.
⁄P < 0.05 compared with control. All results are expressed as mean ± S.E.M. from three independent experiments.
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sugar groups. The ability of Lu1205 to enhance endothelial gap for-
mationwas compromised by 1 U/ml neuraminidase (to digest sialic
acid) but not chondroitinase AC (to digest chondroitin sulfate)treatment (Fig. 2D). Accordingly, treatment of Lu1205 with neur-
aminidase signiﬁcantly reduced endothelial VE-cadherin phosphor-
ylation at Y658 and Y731 in response tomelanoma contact (relative
phospho-VE-cadherin at Y658 and Y731: 0.1 ± 0.0 and 0.1 ± 0.0 for
Fig. 4. CD44v8-v10 transfection enhances the ability of WM35 to induce EC gap formation and VE-cadherin phosphorylation. (A) Western blotting analysis of WM35 cells
transfected with vector only (lane 1), membrane-bound CD44s (lane 2), membrane-bound CD44v8-v10 (lane 3). Plasmid-transfected WM35 cell membrane was extracted
and subject to Western blotting analysis of CD44 expression with 2C5 antibody. (B) Percentage of endothelial gap formation induced by co-culturing HUVECs with WM35
transfected with vector, CD44s or CD44v8-v10. ⁄⁄P < 0.01 compared with vector control. (C) Western blotting analysis of VE-cadherin phosphorylation at Y658, Y685 and Y731
on HUVECs being co-cultured with vector, CD44s or CD44v8-v10-transfected WM35 for 90 min. b-tubulin served as a loading control. The values of relative VE-cadherin
phosphorylation levels for densitometric analysis are shown under each band. All results are representative of at least three independent experiments.
P. Zhang et al. / FEBS Letters 588 (2014) 4573–4582 4579neuraminidase vs. 1.0 ± 0.2 and 1.3 ± 0.3 for chondroitinase AC)
(Fig. 2E).
3.3. CD44v8-v10 but not CD44s-coated microspheres mediates VE-
cadherin junction disassembly
We next used microspheres coated with CD44 immunoprecipi-
tated from Lu1205 or HL-60 cells to evaluate the gap-promoting
capacities of CD44. Immunoprecipitated CD44 was allowed to
adsorb onto 15 lm polystyrene microspheres at levels that mim-
icked the site density of CD44 on Lu1205 cells (Fig. 3A). Lu1205
CD44-coated microspheres were signiﬁcantly more capable of
increasing EC gap size than those coated with CD44 immunopre-
cipitated from HL-60 at equivalent site densities (P < 0.01)
(Fig. 3B). Since HL-60 and SK-Mel-25 express CD44s and Lu1205
cells express CD44v8-v10, we hypothesized that CD44v8-v10 iso-
form was the primary receptor for regulating endothelial junction
breakdown. To test the hypothesis, full length CD44v8-v10 and
CD44s were transfected into COS-7 cells and immunoprecipitated
with 2C5 antibody (Fig. 3C). Then, immunoprecipitated molecules
were absorbed onto microspheres to produce CD44v8-v10 or
CD44s beads which had the same site densities of CD44 isoforms
as Lu1205 (Fig. 3D). To prevent the possible destruction of CD44
structure by vigorous immunoprecipitation procedure, we also
constructed soluble CD44v8-v10 and CD44s molecules which were
devoid of transmembrane and cytosolic domains. The secreted
CD44 isoforms were concentrated and coated onto microspheres.
Both soluble and membrane-bound CD44v8-v10 compared with
their CD44s counterparts exhibited a markedly higher ability to
induce junction breakdown (P < 0.05) (Fig. 3E). To determine theroles of N- and O-glycosylations on CD44v8-v10 in EC junction
breakdown, we generated microspheres with CD44v8-v10 immu-
noprecipitated from transfected COS-7 cells that were cultured in
medium containing 1 mM DMJ to disrupt N-glycosylation, or
2 mM benzyl-GalNAc to prevent O-glycosylation. CD44v8-v10
from DMJ-treated cells induced the gap size equivalent to the con-
trol, whereas CD44v8-v10 from benzyl-GalNAc-treated cells was
deprived of their capacities of inducing endothelial junction break-
down (Fig. 3F). This suggests that sialofucosylated glycans pre-
sented on O-linked carbohydrates structures were responsible for
mediating EC gap formation.
3.4. Overexpression of CD44v8-v10 confers WM35 the ability to induce
EC junction breakdown
Transfection of WM35 with CD44s and CD44v8-v10 plasmids
resulted in high levels of stable CD44 expression (Fig. 4A).
CD44v8-v10-transfected WM35 cells induced signiﬁcantly larger
gap formation and higher levels of phospho-VE-cadherin at Y658
and Y731 in comparison with those transfected with CD44s or vec-
tor (relative phospho-VE-cadherin at Y658 and Y731: 6.9 ± 0.1 and
8.8 ± 0.5 for CD44v8-v10 vs. 0.9 ± 0.3 and 1.4 ± 0.3 for CD44s)
(Fig. 4B and C). Therefore, WM35 receiving CD44v8-v10 gained
the function of promoting EC junction disassembly.
3.5. CD44v8-v10 mediates melanoma extravasation through binding
to E-selectin and promoting VE-cadherin junction disassembly
To characterize the role of CD44 in mediating melanoma cell
transendothelial migration, we next examined the effects of
Fig. 5. CD44 promotes Lu1205 transmigration through inducing endothelial junction breakdown. (A) The transmigration of buffer, scrambled siRNA or CD44-siRNA-
transfected Lu1205 as measured by Boyden chamber assay. ⁄⁄P < 0.01 compared with control cases. (B) The transmigration of Lu1205 cells which were pre-treated with PBS,
0.1 U/ml neuraminidase or 1 U/ml chondroitinase AC. ⁄⁄P < 0.01 compared with control cases. (C) The binding ability of CD44v8-v10-coated beads to E-selectin was analyzed
by the micropipette assay. Top panel: schematic representation of the dual micropipette setup. A CD44v8-v10-coated bead and an E-selectin-coated RBC were held by two
opposing micropipettes and allowed to contact. Binding events were recorded by analyzing the deﬂection of RBC membrane. Bottom panel: The adhesion frequency of
CD44v8-v10-beads to E-selectin was signiﬁcantly higher than that of BSA-beads. 0.1 U/ml neuraminidase treatment markedly reduced the binding afﬁnity of CD44v8-v10/E-
selectin bonds. The results shown are mean ± S.E.M. from 3 independent experiments. ⁄⁄P < 0.01 in comparison to the BSA control. ##P < 0.01 in comparison to CD44v8-v10.
(D) VE-cadherin Y658E construct transfection rescued the transmigration of siCD44-transfected Lu1205. The transfection efﬁciency was assessed by Western blotting to
detect GFP-tagged Y658E VE-cadherin with anti-GFP antibody. Scr: scrambled siRNA; siCD44: CD44 siRNA. ⁄⁄P < 0.01 compared with vector + scr; P < 0.01 compared with
vector+ siCD44 case. Scr: scrambled siRNA. All results are expressed as mean ± S.E.M. from three independent experiments.
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acid moieties on tumor cell migration across HUVEC monolayers.
CD44 siRNA-transfected Lu1205 cells showed a marked reduction
in 4-h transmigration across HUVEC monolayer (Fig. 5A). Further-
more, neuraminidase treatment reduced melanoma migration
potential by 2 folds (Fig. 5B). Fig. 5C showed the speciﬁc binding
of CD44v8-v10 to E-selectin with micropipette aspiration assay
and this binding occurs through sialic acid moieties on CD44
(Fig. 5C). To show the role of VE-cadherin junction breakdown in
CD44-mediated melanoma extravasation, we generated phosp-
homimetic mutant Y658E VE-cadherin which constitutively
induced endothelial barrier disruption [23]. Consistent with the
fact that increased endothelial permeability was permissive to
extravasation of cancer cells, we found that transduction of
Y658E VE-cadherin into HUVECs rescued the ability of CD44-
silenced Lu1205 cells to migrate cross endothelium (Fig. 5D).
4. Discussion
In the current study, we demonstrated that CD44v expressing
Lu1205 rather than CD44s expressing SK-Mel-25 melanoma cells
were capable of triggering VE-cadherin phosphorylation and endo-
thelial gap formation. We also identiﬁed the speciﬁc CD44 spliced
variant, CD44v8-v10, on Lu1205 as a counterreceptor for E-selectin
on endothelium mediating VE-cadherin phosphorylation and facil-
itated melanoma transmigration. The aberrant expressions of
CD44v8-v10 were reported to be associated with tumor metastatic
potentials [40–42]. CD44v8-v10, but not CD44s, suppressed redox
stress-induced Wnt activation, promoting both transcription and
proteasome degradation of c-Myc [43]. CD44v8-v10 silencing
impaired the ability of prostate cancer cells to form colonies [44].
Collectively, CD44v8-v10 may not only be the malignant marker
for melanoma cells, but also serve as a functional receptor to pro-
mote melanoma metastasis.
Our study suggested that neuraminidase treatment which
cleaves sialic acid motifs attenuated EC junction breakdown and
melanoma metastasis, while chondroitin sulfate digestion had no
such effect. CD44 is highly sialic acid-decorated [45]. CD44s binds
hyaluronic acid only upon glycosylation with chondroitin sulfate
[15], while CD44v uses sialic acid to bind to selectins [13]. A previ-
ous study indicated that sialic acid on CD44v upon binding to E-
selectin promoted breast cancer transendothelial migration [46].
However, they did not characterize the glycosylation patterns for
CD44-E-selectin binding and provide amolecular basis for endothe-
lial responses during cancer transendothelial migration. In the cur-
rent study, by using metabolic inhibitors, we provided evidence
that the junction breakdown is tightly regulated by O-glycosylation
but not N-glycosylation on CD44v8-v10. CD44v on colon carcinoma
cells can bind to E-selectin via sialofucosylated O-linked residues
independent of heparin, dermatan, and chondroitin sulfates
[12,13,19]. E-selectin on EC has been shown to mediate transmem-
brane signaling leading to gene expression and endothelial cyto-
skeleton movement, leading to carcinoma transmigration [1,6,7].
By using a novel micropipette binding assay, we demonstrated that
CD44v8-v10 binds to E-selectin with high afﬁnity. Therefore, E-
selectin on HUVEC may serve as the counterreceptor for tumor
CD44v8-v10 to promote endothelial junction breakdown.
CD44 knockdown reduced the % endothelial gap by 2 folds,
compared with scrambled and buffer controls. There may be a
redundant pathway for gap formation. It was reported that
tumor-derived IL-8 may be important for gap formation [29].
Although other factors or receptors in tumor microenvironment
may play roles in triggering the loss of endothelial junction
integrity, as shown in our study, CD44v is the primary mediator
on melanoma cells to regulate the endothelial gap formation.Our data also shows VE-cadherin phosphorylation is one com-
ponent of CD44v-selectin adhesion initiated signaling and if this
component is made less robust, then cells that are less robust at
migration because of the loss of all CD44 (and perhaps other
adverse consequences of gene silencing) are still able to migrate.
In conclusion, CD44 knockdown profoundly diminished mela-
noma-mediated endothelial VE-cadherin disassembly and VE-cad-
herin phosphorylation at Y658 and Y731. Overexpression of
CD44v8-v10 on WM35 enhanced the ability of this non-metastatic
tumor to promote EC junction disassembly. CD44v on melanoma
cells may function as oncogene to promote tumor progression.
These ﬁndings may suggest approaches for designing novel thera-
peutic strategies to treat melanoma metastasis.
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